341
Views
21
CrossRef citations to date
0
Altmetric
Review

Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development

, &
Pages 395-413 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

P. Noel Barrett, Sara J. Terpening, Doris Snow, Ronald R. Cobb & Otfried Kistner. (2017) Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines 16:9, pages 883-894.
Read now

Articles from other publishers (20)

Daniela Iaconis, Francesca Caccuri, Candida Manelfi, Carmine Talarico, Antonella Bugatti, Federica Filippini, Alberto Zani, Rubina Novelli, Maria Kuzikov, Bernhard Ellinger, Philip Gribbon, Kristoffer Riecken, Francesca Esposito, Angela Corona, Enzo Tramontano, Andrea Rosario Beccari, Arnaldo Caruso & Marcello Allegretti. (2023) DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action. Viruses 15:5, pages 1128.
Crossref
Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen, Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon & Pieter Leyssen. (2022) Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort. Scientific Data 9:1.
Crossref
Andrew M. Lewis, Rachael Thomas, Matthew Breen, Keith Peden, Belete Teferedegne, Gideon Foseh, Alison Motsinger-Reif, Daniel Rotroff & Gladys Lewis. (2022) The AGMK1-9T7 cell model of neoplasia: Evolution of DNA copy-number aberrations and miRNA expression during transition from normal to metastatic cancer cells. PLOS ONE 17:10, pages e0275394.
Crossref
Joe W. Cross, Mark Joy, Christopher McGee, Oluwafunmi Akinyemi, Piers Gatenby & Simon de Lusignan. (2020) Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010–2018). Vaccine 38:22, pages 3869-3880.
Crossref
Jackelyn Murray, Kyle V. Todd, Abhijeet Bakre, Nichole Orr-Burks, Les Jones, Weilin Wu & Ralph A. Tripp. (2017) A universal mammalian vaccine cell line substrate. PLOS ONE 12:11, pages e0188333.
Crossref
Belete Teferedegne, Daniel M. Rotroff, Juliete Macauley, Gideon Foseh, Gladys Lewis, Alison Motsinger-Rief & Andrew M. LewisJr.Jr.. (2017) Assessment of potential miRNA biomarkers of VERO-cell tumorigenicity in a new line (AGMK1-9T7) of African green monkey kidney cells. Vaccine 35:41, pages 5503-5509.
Crossref
N. A. Andreani, S. Renzi, G. Piovani, P. Ajmone Marsan, L. Bomba, R. Villa, M. Ferrari & S. Dotti. (2017) Potential neoplastic evolution of Vero cells: in vivo and in vitro characterization. Cytotechnology 69:5, pages 741-750.
Crossref
Yasushi Suzuki, Takato Odagiri, Masato Tashiro & Eri Nobusawa. (2016) Development of an Influenza A Master Virus for Generating High-Growth Reassortants for A/Anhui/1/2013(H7N9) Vaccine Production in Qualified MDCK Cells. PLOS ONE 11:7, pages e0160040.
Crossref
Lauren Parker, Stephen A. Wharton, Stephen R. Martin, Karen Cross, Yipu Lin, Yan Liu, Ten Feizi, Rodney S. Daniels & John W. McCauley. (2016) Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. Journal of General Virology 97:6, pages 1333-1344.
Crossref
Andrea Wolkerstorfer, Dietmar Katinger & Julia Romanova. (2016) Factors affecting the immunogenicity of the live attenuated influenza vaccine produced in continuous cell line. Microbiology Independent Research Journal (MIR Journal) 3:1.
Crossref
Dinja Oosterhoff, Gerard van de Weerd, Gerco van Eikenhorst, Tanja D. de Gruijl, Leo A. van der Pol & Wilfried A. M. Bakker. (2015) Hematopoietic Cancer Cell Lines Can Support Replication of Sabin Poliovirus Type 1. BioMed Research International 2015, pages 1-11.
Crossref
Gerald Aichinger, Barbara Grohmann-Izay, Maikel V. W. van der Velden, Sandor Fritsch, Manuela Koska, Daniel Portsmouth, Mary Kate Hart, Wael El-Amin, Otfried Kistner & P. Noel Barrett. (2015) Phase I/II Randomized Double-Blind Study of the Safety and Immunogenicity of a Nonadjuvanted Vero Cell Culture-Derived Whole-Virus H9N2 Influenza Vaccine in Healthy Adults. Clinical and Vaccine Immunology 22:1, pages 46-55.
Crossref
Ruben O. Donis, Li-Mei Chen, C. Todd Davis, Angie Foust, M. Jaber Hossain, Adam Johnson, Alexander Klimov, Rosette Loughlin, Xiyan Xu, Theodore Tsai, Simone Blayer, Heidi Trusheim, Tony Colegate, John Fox, Beverly Taylor, Althaf Hussain, Ian Barr, Chantal Baas, Jaap Louwerens, Ed Geuns, Min-Shi Lee, Lodewijk Venhuizen, Elisabeth Neumeier & Thedi Ziegler. (2014) Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing. Vaccine 32:48, pages 6583-6590.
Crossref
Belete Teferedegne, Juliete Macauley, Gideon Foseh, Eugenia Dragunsky, Konstantin Chumakov, Haruhiko Murata, Keith Peden & Andrew M. LewisJr.Jr.. (2014) MicroRNAs as potential biomarkers for VERO cell tumorigenicity. Vaccine 32:37, pages 4799-4805.
Crossref
V.H. Basavaraj, G. Sampath, Nagendra R. Hegde, V. Krishna Mohan & Krishna M. Ella. (2014) Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine 32:35, pages 4592-4597.
Crossref
Jennifer Smith, Frederick Koster & Robert Hogan. 2014. Human Respiratory Viral Infections. Human Respiratory Viral Infections 495 522 .
Manfred Reiter, Daniel Portsmouth & P. Noel Barrett. 2014. Industrial Scale Suspension Culture of Living Cells. Industrial Scale Suspension Culture of Living Cells 390 409 .
Leo A van der Pol & Wilfried AM Bakker. (2014) How to choose the correct cell line for producing your viral vaccine: what is important?. Pharmaceutical Bioprocessing 2:3, pages 207-210.
Crossref
M. V. W. van der Velden, R. Fritz, E. M. Pollabauer, D. Portsmouth, M. K. Howard, T. R. Kreil, T. Dvorak, S. Fritsch, T. Vesikari, J. Diez-Domingo, P. Richmond, B. W. Lee, O. Kistner, H. J. Ehrlich, P. N. Barrett & G. Aichinger. (2013) Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population. Journal of Infectious Diseases 209:1, pages 12-23.
Crossref
Lance C. Jennings. (2013) Influenza vaccines: an Asia-Pacific perspective. Influenza and Other Respiratory Viruses 7, pages 44-51.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.